Laura Airas profile picture
Laura
Airas
Professor, Clinical Neurosciences
Professor of Neuroimmunology, MD, PhD
Multiple sclerosis research, @multiplesclerosisresearchfinland, Neuroinflammation research, INFLAMES Flagship

Contact

+358 29 450 4746
+358 50 472 8599
Itäinen Pitkäkatu 4
20520
Turku

Areas of expertise

Neurology
Neuroimmunology
Multiple sclerosis
PET-imaging
MRI

Biography

Laura Airas – a neurologist and neuroimmunologist – directs a multi-disciplinary research group at Neurocenter and the National PET-center at Turku University and the Turku University Hospital. In her clinical practice, she treats patients with multiple sclerosis and other neuroimmunological diseases, and she also leads several clinical trials focusing on multiple sclerosis. Research in her group focuses on the use of advanced MRI techniques and PET imaging to understand the neuroimmunology-related sources of disability in multiple sclerosis and on ways of adapting those approaches for research trials and patient care. She is particularly interested in harnessing noninvasive imaging modalities to dissect biological mechanisms of tissue damage.




Teaching

As a Professor of Neuroimmunology Airas is responsible for neuroimmunological education at the Medical school of the University of Turku. Currently she has under supervision 10 PhD, 4 master’s thesis and 2 extended studies medical students. She participates regularly in domestic and international scientific congresses as a presenter and organizer.

Research

The major goal of research in Airas group is to understand the pathobiology of multiple sclerosis using noninvasive or minimally invasive imaging methods – particularly MRI and PET. The group develops and performs experiments with new MRI techniques and new PET ligands on state-of-the-art imaging equipment housed in the Turku PET Center, to elucidate the biological underpinnings of imaging abnormalities. This will help understand how such abnormalities relate to clinical disability. Corollary goals of the research are to adapt new imaging and soluble biomarker techniques as biologically (and hopefully clinically) relevant outcome measures in both clinical trials and routine patient care, and to apply them to other inflammatory diseases of the central nervous system.


Publications

Sort by: